

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 March 2020 (26.03.2020)



(10) International Publication Number
WO 2020/058472 A1

(51) International Patent Classification:
C12Q 1/6883 (2018.01) *C12Q 1/6886* (2018.01)

(21) International Application Number:
PCT/EP2019/075319

(22) International Filing Date:
20 September 2019 (20.09.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
A 50804/2018 20 September 2018 (20.09.2018) AT

(71) Applicants: **TAMIRNA GMBH** [AT/AT]; Leber-
strasse 20, 1110 Vienna (AT). **MEDIZINISCHE**
UNIVERSITÄT WIEN [AT/AT]; Spitalgasse 23, 1090
Vienna (AT).

(72) Inventors: **HACKL, Matthias**; Setzgasse 25/4, 2102
Bisamberg (AT). **ASSINGER, Alice**; Neustiftgasse 56/14,

1070 Vienna (AT). **STARLINGER, Patrick**; Anna Spiegel
Forschungsgebäude, Währinger Gürtel 18-20, 1090 Vienna
(AT).

(74) Agent: **LOIDL, Manuela** et al.; REDL LIFE SCIENCE
PATENT ATTORNEYS, Donau-City-Strasse 11, 1220 Vi-
enna (AT).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) Title: MICRO-RNA SIGNATURES FOR THE PREDICTION OF LIVER DYSFUNCTION

Fig. 2B





Fig. 2C



(57) Abstract: The invention relates to an *in vitro* method of determining a subject's risk of liver dysfunction, specifically after partial liver resection, said method comprising the steps of providing a sample from said subject, determining in said sample the expression level of at least one miRNA, selected from the group consisting of miR-151a, miR-192 and miR-122, and comparing these expression level(s) with at least one reference expression level, or identifying the ratios of the expression levels of miR-151a to miR-192 and/or of mi R-122 to mi R-151a and comparing said expression level ratios with reference expression level ratios, and classifying the sample from the outcome of the comparison into one of at least two classes, wherein each class is one of the at least two categories "high-risk" and "low-risk".

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))